SGLT2 inhibition: an effective therapeutic approach in the treatment of diabetes mellitus?

被引：0
|
作者：
Rudofsky, G. [1 ]
Ruessmann, H. -J.
Siegmund, T. [2 ]
机构：
[1] Univ Klinikum Heidelberg, Abt Innere Med & Klin Chem 1, D-69120 Heidelberg, Germany
[2] Stadt Klinikum Munchen GmbH, Klinikum Bogenhausen, Klin Endokrinol Diabetol & Angiol, Munich, Germany
来源：
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT | 2013年 / 138卷 / 22期
关键词：
blood pressure; type; 2; diabetes; weight reduction; glucosuria; drug therapy; Sodium Glucose Linked Transporter (SGLT); INADEQUATE GLYCEMIC CONTROL; DOUBLE-BLIND; DAPAGLIFLOZIN TREATMENT; ADD-ON; TYPE-2; KIDNEY; METFORMIN; CANAGLIFLOZIN; TRANSPORT; WEIGHT;
D O I：
10.1055/s-0032-1333023
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Since end of 2012 a new therapeutical approach for the treatment of type 2 diabetes is available in Germany. It relies on the modulation of glucose re-absorption in the kidney by inhibition of so called Sodium Glucose Linked Transporters (SGLT) thereby leading to therapeutical glucosuria. Putting the kidney in the centre of therapeutical approach of glucose regulation is unfamiliar for physicians. Therefore, it is helpful to elucidate the underlying renal mechanisms and to present the advantages and disadvantages of this new therapeutic class. © Georg Thieme Verlag KG, Stuttgart New York.
引用
收藏
页码：1172 / 1177
页数：6
相关论文
共 50 条
  • [41] The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review
    Janet B. McGill
    Diabetes Therapy, 2014, 5 : 43 - 63
  • [42] SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases
    Wanner, Christoph
    Marx, Nikolaus
    DIABETOLOGIA, 2018, 61 (10) : 2134 - 2139
  • [43] SGLT2 inhibitors in the treatment of type 2 diabetes
    Hasan, Farhad M.
    Alsahli, Mazen
    Gerich, John E.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 104 (03) : 297 - 322
  • [44] Does SGLT1 Inhibition Add Benefit to SGLT2 Inhibition in Type 2 Diabetes?
    Pitt, Bertram
    Bhatt, Deepak L.
    CIRCULATION, 2021, 144 (01) : 4 - 6
  • [45] Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus
    Kaushal, Shaveta
    Singh, Harmanjit
    Thangaraju, Pugazhenthan
    Singh, Jasbir
    NORTH AMERICAN JOURNAL OF MEDICAL SCIENCES, 2014, 6 (03) : 107 - 113
  • [46] Therapeutic Targeting of SGLT2: A New Era in the Treatment of Diabetes and Diabetic Kidney Disease
    Shaffner, James
    Chen, Bohan
    Malhotra, Deepak K.
    Dworkin, Lance D.
    Gong, Rujun
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [47] The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition
    Haedersdal, Sofie
    Lund, Asger
    Nielsen-Hannerup, Elisabeth
    Maagensen, Henrik
    van Hall, Gerrit
    Holst, Jens J.
    Knop, Filip K.
    Vilsboll, Tina
    DIABETES, 2020, 69 (12) : 2619 - 2629
  • [48] SGLT2 Inhibitors to Control Glycemia in Type 2 Diabetes Mellitus: A New Approach to an Old Problem
    Jabbour, Serge A.
    POSTGRADUATE MEDICINE, 2014, 126 (01) : 111 - 117
  • [49] Mechanistic effects of SGLT2 inhibition on blood pressure in diabetes
    Yaribeygi, Habib
    Atkin, Stephen L.
    Sahebkar, Amirhossein
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2019, 13 (02) : 1679 - 1683
  • [50] SGLT2 Inhibition in Kidney Transplant Recipients with Diabetes.
    Guthoff, M.
    Mahling, M.
    Nadalin, S.
    Heyne, N.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 554 - 554
12345